Sweden· SE-20231217000024
Nintedanib Glenmark 150 mg Kapsel, mjuk
A medicinal product containing nintedanib, registered in Sweden by Glenmark Arzneimittel GmbH.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Nintedanib
- Manufacturer
- Glenmark Arzneimittel GmbH
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20231217000024
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nintedanib in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IcelandAgarfNorameda UAB
- SpainNINTEDANIB ACCORD 150 MG CAPSULAS BLANDAS EFGAccord Healthcare S.L.U.
- PolandNintedanib AccordAccord Healthcare S.L.U.
- FranceNINTEDANIB ACCORD 150 mg, capsule molleACCORD HEALTHCARE (ESPAGNE)
- SwitzerlandNintedanib Leman 150 mg, capsule molleLeman SKL SA
- IrelandOfev 150 mg Soft capsuleBoehringer Ingelheim International GmbH
- NorwayNintedanib AccordAccord Healthcare S.L.
- NetherlandsGevesla 100 mg, zachte capsulesSandoz B.V.
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Nintedanib Cipla, Nintedanib Ratiopharm
- Belgium · Nintedanib Accordpharma, Nintedanib Eg
- Cyprus · Nintedanib Teva
- Czechia · Nintedanib Glenmark, Nintedanib Sandoz
- Germany · Nintedanib, Nintedanib 1 A Pharma
- Denmark · Nintedanib "sandoz", Nintedanib Glenmark
- Estonia · Agarf, Nintedanib Sandoz
- Spain · Nintedanib, Nintedanib Accordpharma
- Finland · Nintedanib Glenmark, Nintedanib Ratiopharm
- France · Nintedanib Arrow, Nintedanib Biogaran
- United Kingdom (Northern Ireland) · Nintedanib, Nintedanib Accord Healthcare
- Greece · Nifib, Nindraf
- Croatia · Gevesla, Nintedanib Accordpharma
- Hungary · Nintedanib Accordpharma, Nintedanib Onkogen
- Ireland · Nintedanib Accordpharma, Nintedanib Clonmel
- Iceland · Agarf, Nintedanib Accord
- Italy · Nintedanib Accordpharma, Nintedanib Aurobindo
- Liechtenstein · Nintedanib Accord, Nintedanib Viatris
- Lithuania · Agarf, Nintedanib Sandoz
- Luxembourg · Nintedanib Eg, Nintedanib Eurogenerics
- Latvia · Agarf, Nintedanib Sandoz
- Malta · Nifiden Adalvo, Nintedanib Adalvo
- Netherlands · Gevesla, Nintedanair
- Norway · Nintedanib Accord, Nintedanib Devatis
- Poland · Nintedanib, Nintedanib Accordpharma
- Portugal · Nintedanib Accordpharma, Nintedanib Eugia
- Romania · Gevesla, Nintedanib Dr. Reddy’s
- Slovenia · Nintedanib Accordpharma, Nintedanib Stada
- Slovakia · Nintedanib Stada, Nintedanib Teva
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/306ccffd-f35b-4c12-8435-8b8e1f92cbfd GET /v1/drugs/306ccffd-f35b-4c12-8435-8b8e1f92cbfd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"SmPC",
"sPAR",
"PAR",
"PL",
"sRMP"
],
"se_npl_id": "20231217000024",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20231217000024",
"product_doc_link": "https://docetp.mpa.se/LMF/Nintedanib%20Glenmark%20capsule%2C%20soft%20ENG%20SmPC_09001bee84ecfd97.pdf"
}See everything about nintedanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.